Accumed will develop its disruptive balloon platform, ARIVE, in conjunction with POBA Medical, focusing on multiple applications for ARIVE in the PCI, PAD and other markets.
FARMINGTON HILLS, MICHIGAN, USA, April 22, 2022 /EINPresswire.com/ — Accumed Radial Systems is pleased to announce a strategic agreement with POBA Medical, Inc., to develop prototypes of our unique, patented and disruptive Accumed Radial Intra Vascular Extension (ARIVE) platform. POBA will develop ARIVE prototypes for various applications in conjunction with Accumed Radial teams while providing POBA’s design, manufacturing and scale-up expertise. POBA will simultaneously invest in Accumed Radial. Terms of the agreement remain undisclosed.
Accumed Radial’s ARIVE platform is a low-threshold interventional cardiology balloon platform aimed at improving procedural outcomes by disrupting balloon function. Currently, interventional cardiology balloons obstruct blood flow when inflated during procedures such as balloon angioplasty, or as drug-coated balloons, or to stem dissections. This considerably limits the deployment time of the balloon. In contrast, the ARIVE balloon, when inflated, allows blood infusion/flow, and therefore can be used for a much longer period at the application site, compared to existing balloons. Using existing balloon materials and manufacturing techniques, ARIVE is developed with a low regulatory threshold in mind, and therefore a short path to market, creating significant innovations in all applications where balloons are used. In cardiology alone, this addressable market in the United States alone is estimated at more than $1 billion.
“Accumed Radial warmly welcomes POBA to its growing list of partners and investors. POBA is a pioneer in balloon manufacturing, and they are a great partner in prototyping the capabilities of our ARIVE platform. We appreciate their validation of the ARIVE platform thanks to their investment“.
– Raj Riswadkar, CEO
“We are delighted that POBA is investing in Accumed Radial Systems and in particular our unique and disruptive ARIVE platform. Considering the POBA team’s 25+ years of balloon expertise, we appreciate the vote of confidence their investment places in ARIVE’s value proposition and manufacturability.
– Patrick O’Neill, Founder and President
“POBA Medical is thrilled to partner with Accumed Radial Systems and its world-class group of clinical entrepreneurs and inventors. This partnership allows us to leverage the ability of our young team to create new solutions using our expertise in balloons and catheters. As interventional radial access approaches over 90% of all interventional access, we want to help create the best tools available. »
– Dan Kasprzyk, Founder and CEO
About Accumed Radial
Accumed Radial designs and develops medical devices for interventional cardiology; a medical specialty that treats the current global epidemic of heart disease. Accumed Radial is developing a portfolio of short-term devices that are desired and needed by interventional cardiologists to improve clinical outcomes. Accumed Radial strives to develop devices that are innovative, patented, with little or no competition and with easier/simpler FDA regulatory requirements. Accumed Radial plans to take some of its product ideas to market launch, while actively working on various commercial options for our other products, such as partnerships, licensing agreements or outright divestitures.
About POBA Medical
POBA Medical Inc., a leading Flagstaff AZ-based medical balloon developer and manufacturer, specializes in the development of angioplasty-style balloons and catheters, including high-volume production. They have extensive abilities to customize balloon specifications to suit consumer needs or wants with a varied material selection. Balloon capacities range in diameters from 1mm to 45mm and lengths from 5mm to 350mm with materials ranging from PET, nylon, Pebax, polyurethane, multi-layer blends and Poba51™. Over its short history, POBA has designed catheters and balloons for hundreds of customers, currently sells over 100 ready-to-use chamfr™ balloons, all from a 12,000 square foot manufacturing space at Flagstaff AZ, which is being expanded.